Candel Therapeutics presents preclinical data with CAN-3110 in Melanoma model at SITC annual Meeting

Proactive - Interviews for investors

Candel Therapeutics Chief Scientific Officer Dr. Francesca Barone joined Steve Darling from Proactive to share news the company is presenting at the Society for Immunotherapy of Cancer (SITC) conference. Barone, the company’s Chief Scientific Officer shared details on CAN-3110, a first-in-class oncolytic viral therapy designed to selectively replicate within cancer cells. CAN-3110 is engineered to minimize effects on healthy cells while triggering a potent immune response within tumors, a promising innovation for treating difficult cancers like recurrent high-grade glioma and resistant melanoma. “Immunotherapy has transformed melanoma treatment, but many patients remain resistant,” Dr. Barone explained. Preclinical melanoma data shows CAN-3110 significantly reduces tumor burden while activating the immune system in cell models. The therapy’s success in melanoma trials also hints at broader applications, with Dr. Barone citing potential future investigations into triple-negative breast cancer and sarcoma. With a strong safety profile, Candel Therapeutics is now considering targeted preclinical trials to assess CAN-3110’s impact across additional challenging cancers. This novel therapeutic could offer new hope for patients with limited options, potentially transforming treatment landscapes for resistant tumor types. #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough #proactiveinvestors #candeltherapeuticsinc #nasdaq #OncolyticVirus #Immunotherapy #CancerResearch #MelanomaTreatment #CAN3110 #FrancescaBarone #SITC #BiotechNews #CancerBreakthrough#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews